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Objective: to investigate the factors related to medication adherence and its relation to Health-
Related Quality of Life (HRQoL) in elderly people with diabetic retinopathy. Method: one hundred 
(n=100) elderly outpatients with diabetic retinopathy taking antihypertensives and/or oral 
antidiabetics/insulin were interviewed. Adherence was evaluated by the adherence proportion 
and its association with the care taken in administrating medications and by the Morisky Scale. 
The National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) was used to evaluate 
HRQoL. Results: most (58%) reported the use of 80% or more of the prescribed dose and care 
in utilizing the medication. The item “stopping the drug when experiencing an adverse event”, 
from the Morisky Scale, explained 12.8% and 13.5% of the variability of adherence proportion 
to antihypertensives and oral antidiabetics/insulin, respectively. Conclusion: there was better 
HRQoL in the Color Vision, Driving and Social Functioning domains of the NEI VFQ-25. Individuals 
with lower scores on the NEI VFQ-25 and higher scores on the Morisky Scale presented greater 
chance to be nonadherent to the pharmacological treatment of diabetes and hypertension.
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Introduction
The visual acuity decrease in the elderly contributes 
expressively to accentuate their dependence, by the 
changes related to social and psychological aspects, the 
gradual loss of autonomy, self-care and quality of life(1). 
Diabetic retinopathy (DR) constitutes one of the most 
incapacitating microangiopathic complications in older 
patients with diabetes mellitus (DM)(2) and it is divided 
into two phases: non-proliferative and proliferative. 
Non-proliferative DR is characterized by intra-retinal 
alterations associated with the increase in capillary 
permeability and, occasionally, to vascular occlusion(3). 
In the progression of non-proliferative DR, the formation 
of new veins can be observed at the vitreous interface 
of the retina, constituting the proliferative DR(3).
The risk factors for DR are basically hyperglycemia 
and hypertension(4), pointing to the importance of the 
regular use of medications to control glycemia and 
pressure levels, in order to prevent the manifestation 
of the disease and/or its evolution. This is an 
important issue among the elderly population that has 
demonstrated a tendency to nonadherence(5). Moreover 
among those affected by DR, the failure to adhere to 
drug therapy results in the inadequate control of the 
glycemia and hypertension, in the progression of retinal 
complications, and in the worsening of the visual acuity 
that, in turn, compromises the quality of life of these 
individuals.
The health-related quality of life (HRQoL) has 
been thoroughly studied in the elderly population. 
Epidemiological and clinical studies have analyzed the 
perception of health status and HRQoL among the 
elderly, as well as the impact of their disease and its 
respective treatment in HRQoL(6). However, only few 
researches report the evaluation of vision-related 
quality of life(7).
Therefore, assuming that medication adherence 
in the elderly with DR could be influenced by 
sociodemographic conditions, low visual acuity and 
HRQoL, this study intended to analyze the correlation/
association between medication adherence and the 
sociodemographic/clinical variables and HRQoL of the 
elderly with DR. More specifically, the study evaluates: 
1. the elderlys’ adherence to the specific medications 
(oral antidiabetics/insulin and antihypertensives); 
2. vision-related quality of life of these individuals; 
and 3. the relation between medication adherence, 
sociodemographic/clinical variables and vision-related 
quality of life.
Methods
Design, Settings and Sample
This descriptive, cross-sectional, correlational 
study was conducted in an Ophthalmological outpatient 
clinic of a university hospital in the interior of the state 
of São Paulo, Brazil. The study recruited one hundred 
(100) elderly individuals with medical diagnosis of 
diabetic retinopathy in use of antihypertensives and/or 
oral antidiabetics/insulin. Elderly presenting: 1. Visual 
acuity loss occurring secondary to multiply causes 
(glaucoma, congenital ocular diseases, media opacity); 
and 2. Ocular surgeries thirty (30) days or less before 
the data collection(8) were excluded.
Data Collection
Data was gathered from February up to December 
2008 by structured individual interviews. Data regarding 
the ophthalmological status were obtained from the 
patients’ medical records, right after the medical 
consultation, and data concerning adherence and HRQoL 
by interview.
Instruments
- Sociodemographic and clinical data: the instrument was 
composed of three parts: I. Sociodemographic profile; 
II. Clinical characterization; III. Ophthalmological 
evaluation: visual acuity for distance (Snellen Optometric 
Chart) and for near vision (Jaeger Table) in the better-
seeing eye, with optical corrections if the patients made 
use. The elderly were grouped according to visual acuity 
for distance(9) and near vision(10); with minor adaptations.
- National Eye Institute Vision Functioning Questionnaire 
(NEI VFQ-25), Brazilian version(11): questionnaire 
assessing the influence of visual impairment on HRQoL. 
The 25-item NEI VFQ comprises 12 domains: general 
health, general vision, ocular pain, near activities, 
distance activities, social functioning, mental health, 
role difficulties, dependency, driving, color vision and 
peripheral vision. Each subscale is scored so that zero 
(0) represents the lowest and one hundred (100) the 
best possible score. In the present study, the value of 
internal consistency, assessed by Cronbach’s alpha was 
0.95.
- Brazilian Version of the Morisky Medication Adherence 
Scale(12), composed of four questions relative to: 
forgetfulness, carelessness, stopping the drug when 
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feeling better or when experiencing adverse events. 
The answers are structured on a Likert-type scale, with 
four or five options to each item. The sum of the four 
items generates a score that varies from 4 up to 18. 
The lower is the score, greater is the favorability of 
adherence to the treatment. For individuals using both 
antihypertensives and oral antidiabetics/insulin, the 
Morisky Scale was applied separately for each group of 
medications.
- Measurement of Medication Adherence: adherence 
was evaluated regarding the proportion and the global 
evaluation of adherence.
- Proportion of adherence: evaluated according to four 
charts that comprehend: 1. Class, dose and dosage 
form of all prescribed drugs; Use of each of the 
prescribed medications: 2. In the 24 hours prior to the 
interview; 3. During the week prior to the interview; 
and 4. Over the month preceding to the interview. The 
purpose of Charts 2 and 3 was to facilitate obtaining 
more accurate answers by minimizing the bias of 
memory. Adherence was calculated based on the 
omitted doses, informed by the patient, by using the 
following calculation: [(prescribed doses – omitted 
doses) x 100 / prescribed doses](13). The respondents 
taking doses superior to those prescribed have their 
adherence value converted to the corresponding 
index, inferior to 100% (i.e. a patient taking 120% 
of the prescribed treatment was described as taking 
80% of the dose)(14). For those taking more than one 
class of medication, the final proportion of adherence 
was calculated by the average of the percentages 
of adherence of each medication. The proportion of 
adherence was considered as a continuous variable 
(taking the average of the proportion of all prescribed 
medications used), and as a categorical variable: 
adequate dose (for a proportion equal or superior 
to 80% of the prescribed dose) and insufficient dose 
(when the dose taken did not reach 80% of the 
prescribed).
- Global evaluation of adherence: aside from the 
proportion of adherence, its dosage form was also 
evaluated, that is, the number of times the medication 
was taken and its association with temporal markers: 
fasting, breakfast, lunch and dinner. Therefore, for 
the global evaluation of adherence, the patients were 
classified in two groups: I: Adherent: adequate dose and 
care; II: Nonadherent: inadequate dose and/or care.
The order of administration of NEI VFQ-25, Morisky 
Scale and Medication Adherence Identification was 
varied randomly to minimize order effects.
Statistical Analysis
The Statistical Package for Social Sciences software 
(SPSS - version 15.0 for Windows) was used for the 
following analyses: descriptive, comparative (Chi-
Squared and Fisher’s Exact, Mann-Whitney, Kruskal-
Wallis tests and Spearman correlation coefficient); 
logistic regression with stepwise criterion of variables 
selection. The strength of correlation coefficients (r) 
was classified as: little if any (values between 0 and 
0.25), low (0.26 – 0.49), moderate (0.5 – 0.69), high 
(0.70 – 0.89) and very high correlation (0.9 – 1)(15). 
Non-parametric tests were used since the distribution 
of the variables was not normal. The significance level 
adopted was 5%.
Ethical aspects
All enrolled patients signed the Informed Consent 
Form. The study was approved by the local ethics 
committee (Document no. 777/2007).
Results
Sample characterization
The sample was predominantly female (62%), 
mean age of 69.5(7.1) years, schooling of 4.0(3.0) years, 
professionally inactive (64%). The majority of patients 
(85%) presented DM and hypertension and 25% only 
DM. Large portion of the sample had normal or near-
normal distance vision (44%) and near vision (63%). 
Fifty-two individuals presented the non-proliferative 
DR; 46 proliferative DR and 2 experienced both. The 
DR diagnosis length was in average 32.7(25.6) months 
varying from 6 up to 180 months.
Evaluation of Vision-Related Quality of Life (NEI VFQ-
25)
The highest scores were observed in the “Color 
Vision”, “Driving” and “Social Functioning” domains, 
with a tendency to better HRQoL in these domains. 
The lowest score was obtained in the “General Health” 
domain.
Measurement of Medication Adherence
Among the sample, 85% utilized antihypertensive 
drugs and all utilized oral antidiabetics and/or insulin, 
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48% being insulin-dependent. The Morisky Scale was 
applied separately for the hypertensive medications 
and for the oral antidiabetics/insulin. The averages 
obtained were 5.4(1.7) and 5.1(1.6), respectively. 
During the month that preceded the interview, the 
individuals used 86.3% of the doses prescribed for 
hypertension and/or DM. Most of the studied group 
(58%) was considered adherent because they reported 
having utilized 80% or more of the prescribed dose 
and having taken the necessary care in utilizing the 
medications (Table 1).
The Morisky Scale, though treated by some authors 
as a measure of adherence, actually unites four factors 
that predict patient medication-taking behavior, without 
measuring adherence itself. Therefore, the correlation 
between the Morisky Scale (total score and score of 
each item) and the proportion of adherence was tested 
initially (Table 2).
Negative correlations of low magnitude were 
observed between the total score of the Morisky Scale 
and the proportion of adherence of antihypertensives 
and antidiabetics, indicating that the more the patients 
revealed concordance with the items on the Morisky Scale, 
which lead to nonadherence, the less they correctly utilized 
the prescribed medications. The proportion of adherence 
of both antidiabetic and antihypertensive medications 
correlated negatively, with low to moderate magnitude, 
with the last two items (stopping the drug when feeling 
better or when experiencing adverse events).
A multivariate linear regression analysis was 
performed to investigate which item(s) of the Morisky 
Scale effectively explained the variability of the 
proportion of adherence (Table 3). Only the item 4 
(stopping the drug when experiencing an adverse event) 
explained the variability of the proportion of adherence 
for both the antihypertensive (12.8%) and the oral 
antidiabetics/insulin drugs (13.5%).
Table 1 – Medication adherence according to the criteria of proportion, Morisky Scale and classification in accordance 
with the adequacy of the dose and care in taking the medication (n=100). Campinas, SP, Brasil, 2008
Proportion of medication adherence (%)
Medications Total (n=100) Diabetic individuals (n=15) Diabetic and hypertensive individuals (n=85)
Antidiabetics 87.5 (19.5) 86.7 (13.3) 88.1 (20.1)
Antihypertensives 86.2 (21.1) --- 88.2 (19.6)
Antidiabetics and Antihypertensives 86.3 (18.0) --- 87.5 (18.1)
Morisky Scale
Medications Items Total (n=100) Diabetic individuals (n=15)
Diabetic and hypertensive 
individuals (n=85)
Oral antidiabetics and/or insulin Total 5.1 (1.6) 4.6 (1.0) 5.2 (1.7)
Item 1 1.4 (0.7) 1.3 (0.7) 1.4 (0.7)
Item 2 1.4 (0.9) 1.1 (0.5) 1.5 (0.9)
Item 3 1.1 (0.3) 1.1 (0.3) 1.1 (0.3)
Item 4 1.3 (0.7) 1 1.3 (0.8)
Antihypertensives Total 5.4 (1.7) --- 5.4 (1.7)
Item 1 1.5 (0.8) --- 1.5 (0.8)
Item 2 1.5 (0.9) --- 1.5 (0.9)
Item 3 1.1 (0.4) --- 1.1 (0.4)
Item 4 1.3 (0.7) --- 1.3 (0.7)
Classification of global adherence to medication therapy (n=100)
Adherent 58%
Table 2 – Correlations between the Morisky Scale and the proportion of medication adherence (n=100). Campinas, 
SP, Brasil, 2008
Morisky Scale
Proportion of Medication Adherence*
Antidiabetics Antihypertensives Both
r p-value r p-value r p-value
Antihypertensives (n=85) Total -- -- -0.45 <0.001 -0.48 <0.001
Item 1 -- -- -0.05 0.624 -0.09 0.409
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Morisky Scale
Proportion of Medication Adherence*
Antidiabetics Antihypertensives Both
r p-value r p-value r p-value
Antihypertensives (n=85) Item 3 -- -- -0.40 <0.001 -0.40 <0.001
Item 4 -- -- -0.59 <0.001 -0.59 <0.001
Oral Antidiabetics /Insulin
(n=100)
Total -0.38 <0.001 -- -- -0.42 <0.001
Item 1 -0.07 0.471 -- -- -0.01 0.910
Item 2 -0.15 0.137 -- -- -0.202 0.044
Item 3 -0.43 <0.001 -- -- -0.39 <0.001
Item 4 -0.40 <0.001 -- -- -0.52 <0.001
r= Coefficient of Spearman’s correlation.
Morisky Scale: lower scores indicate better favorability for medication adherence. Items 1 and 2: range from 1 up to 5; items 3 and 4: range from 1 up to 4.
*The proportion of medication adherence presented here corresponds to the percentage of the used doses over the last month.
Analysis of the association between adherence and 
the sociodemographic and clinical variables and 
HRQoL
With the purpose of identifying the factors possibly 
associated with adherence to medication therapy among 
the elderly, an exploratory analysis was performed, 
testing the correlation between adherence (analyzed as a 
continuous variable and the score obtained on the Morisky 
Scale) and the sociodemographic and clinical variables.
The correlation matrix among adherence and the 
sociodemographic and clinical variables demonstrated 
that the proportion of adherence was positively correlated 
with the monthly income (r=0.39; p<0.000), only for 
the use of the oral antidiabetics/insulin. The number of 
associated medications was weakly positively correlated 
with the item 2 (carelessness – r=0.28; p=0.005 for use 
of antidiabetics/insulin and r=0.27; p=0.013 for use of 
antihypertensives) and the total score of the Morisky 
Scale (r=0.23; p=0.025 for oral antidiabetics/insulin 
exclusively); and weakly negatively correlated with the 
item 3 (stopping the drug when feeling better – r=-
0.28; p=0.01 for use of antidiabetics/insulin; r=-0.27; 
p=0.014 for use of antihypertensives). This suggests that 
the greater the number of associated medications, the 
greater the total score, which points to nonadherence, 
and the greater the concordance of the patient in being 
careless in the use of the medications. It also indicates 
that the greater number of medications in use, the less 
the patient stops using them when feeling better.
For the analysis of factors associated to global 
adherence, an analysis of logistic regression was 
performed, including as independent variables: visual 
acuity (for distance and near vision), vision-related 
quality of life (NEI VFQ-25) and the factors related to 
the nonadherence, measured by the Morisky Scale. 
The adherence as a dependent variable was treated as 
categorical: Adherent (adequate dose and carefulness 
– Group I) and Nonadherent (inadequate dose and/or 
carelessness – Group II) (Table 4).
Table 3 – Analysis of multivariate linear regression of the proportion of adherence to the medications, according to 
the Morisky Scale (n=100). Campinas, SP, Brasil, 2008
Morisky Scale (antihypertensives) (n=85)
Proportion of adherence to the antihypertensives
Beta (SE)† p-value R2 Partial
Item 1* -0.078 (0.119) 0.512 0.005
Item 2* -0.163 (0.125) 0.197 0.022
Item 3* -0.348 (0.220) 0.119 0.027
Item 4* -0.462 (0.189) 0.017 0.128
Morisky Scale (antidiabetics/insulin) (n=100)
Proportion of adherence to the antidiabetics/insulin
Beta (SE)† p-value R2 Partial
Item 1* -0.136 (0.119) 0.258 0.011
Item 2* -0.154 (0.120) 0.204 0.017
Item 3* -0.369 (0.211) 0.083 0.030
Item 4* -0.446 (0.158) 0.006 0.135
*Variables transformed into ranks due to the absence of normal distribution. †Beta: value of the estimate or angular coefficient (slope) in the line of 
regression; SE: standard error of beta; R2: coefficient of determination. R2 Total (antihypertensives): 0.180. Intercept (SE): 88.15; p<0.001. R2 Total 
(antidiabetics/insulin): 0.193. Intercept (SE): 106.24; p< 0.001.
Table 2 - continuation
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The analysis indicates that the vision-related quality 
of life and the Morisky Scale score (for antihypertensives 
and oral antidiabetics/insulin) influenced the medication 
adherence: individuals with lower scores on the NEI 
VFQ-25 and higher scores on the Morisky Scale have a 
greater chance of becoming nonadherent.
Discussion
This study analyzed the associations observed 
between medication adherence and the sociodemographic/
clinical variables and HRQoL of the elderly with DR. The 
observed average proportion of medication taken was 
above 80% for the two classes of medication, indicating 
adherence. However, when the evaluation of the dose 
and care relative to the prescription was associated to 
this proportion, approximately half of the individuals 
(42%) revealed nonadherence, characterized by the 
associations: adequate use of the dose and inadequate 
care, insufficient dose and adequate care and inadequate 
dose and care.
The only variable observed in relation to the 
medication taken was the monthly income among 
the patients using oral antidiabetics/insulin. This is 
a significant corroborated finding, considering that a 
large part of the medications for hypertension and DM 
is available to the Brazilian population free of charge 
at the public health services. The association between 
nonadherence and a worse financial situation was 
also reported among HIV patients(16). Income was also 
a risk factor for both nonadherence and secondary 
hospitalization in the elderly(17). These data reveal 
the importance of considering the basic necessities of 
the population, particularly among the elderly, in the 
planning of intervention dealing with the promotion of 
adherence to the therapy.
Regarding the correlation analysis, although the 
items linked to carelessness and stopping the drug when 
feeling better have been correlated to the proportion of 
adherence, this was effectively explained by the item 4, 
as shown on the regression analysis, which refers to the 
interruption of the medication when feeling worse when 
taking it. Therefore, attention should be given to the 
relevance of the patient’s exact perception of “worse”. 
In other words, it is necessary to investigate if this 
perception actually refers to a clinical event, such as 
hypotension symptoms or hypoglycemia, for example. If 
the investigation points to adverse events that worsen 
the clinical manifestations or compromise the patient’s 
well-being, the therapeutic regimen must be reviewed. 
If the perception is not associated to any event that 
configures a clinical damage, educational interventions 
should be designed, aimed at self-evaluating signs 
and symptoms, blood pressure and glycemic levels; as 
Table 4 – Analysis of univariate logistic regression for global medication adherence (n=100). Campinas, SP, Brasil, 
2008
Variables Categories p-value O.R* CI 95%*
Visual acuity for distance vision Profound low vision or blindness (ref.) -- 1.00 --
Moderate low vision 0.399 1.62 0.53 – 4.94
Normal 0.056 2.95 0.97 – 8.94
Visual acuity for near vision Blindness (<J6) -- 1.00 --
Low vision (J4, J5 and J6) 0.257 2.17 0.57 – 8.26
Normal (J1, J2 and J3) 0.069 2.51 0.93 – 6.78
NEI VFQ-25 (categorized) 0-50 (ref.) -- 1.00 --
50-74 0.283 1.92 0.58 – 6.32
75-100 0.024 3.34 1.17 – 9.50
Morisky Scale
Antihypertensives
≥8 points (ref.) -- 1.00 --
6-7 points 0.220 2.70 0.55 – 13.20
4-5 points 0.010 6.53 1.57 – 27.21
Does not use 0.077 4.50 0.85 – 23.80
Morisky Scale
Oral Antidiabetics and/or Insulin
Total score (for each 1 point) -- 1.00 --
0.007 0.68 0.51 – 0.90
Morisky Scale
Oral Antidiabetics and/or Insulin 
(categorized)
≥7 points (ref.) -- 1.00 --
5-6 points 0.013 5.10 1.42 – 18.32
4 points 0.002 6.35 1.98 – 10.37
*O.R. (Odds Ratio) for medication adherence (n= 42 Nonadherent and n= 58 Adherent). CI 95% = Confidence Interval of 95% for the risk of odds ratio. 
Ref.: category utilized as the reference for the analysis.
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well as strategies that allow improve the patient’s self-
efficacy in the correct handling of the prescribed drug 
therapy.
Concerning the association between the number of 
medications in use and the Morisky score, educational 
actions should include strategies that facilitate the 
elderly’s comprehension of the importance of the 
uninterrupted use of the medications, both for obtaining 
as well as for maintaining the desired therapeutic effect, 
once they were using a greater number of medications 
and reported greater carelessness in taking them and 
stopping their use when they were feeling better.
The distinction between the Proportion of 
Adherence/Morisky Scale and the sociodemographic and 
clinical variables should be emphasized. Although the 
relation between the Morisky Scale and the Proportion 
of Adherence has been established and even though it 
consists of a significant finding, the two measures do not 
quantify the same construct.
The adherence behavior is a dynamic process, 
difficult to be measured, and for which it there is no 
standard measurement or gold standard. In the clinical 
practice, the Morisky Scale has shown to be effective 
for the identification of some of the reasons for 
nonadherence and, at times, it has been associated with 
outcomes(18).
The studies related to adherence focus mainly 
on the reduction of symptoms and on the evaluation 
of measurement instruments. However, the relations 
between medication adherence and the global evaluations 
of well-being, which would allow comprehending and 
better guiding the treatment(19), are not frequently 
examined. The present study provides significant 
contribution to this matter, by measuring the vision-
related quality of life and testing it as an influencing 
variable on medication adherence.
In the evaluation of the NEI VFQ-25, relatively 
high scores were observed in all the domains of the 
instrument. However, it was verified that the perception 
of “worse” vision-related quality of life was associated 
with the chance of 3.34 times of nonadherence. It is 
interesting to note that visual acuity was not associated 
to adherence, which makes it possible to infer that 
it is not the drop in visual acuity that compromises 
adherence, but one’s perception of how much this drop 
negatively interferes in his/her quality of life.
Considering that the studies on the relation 
between quality of life and medication adherence 
are still scarce in the literature, the development of 
future investigations is suggested, by simultaneously 
applying a generic measure of HRQoL and analyzing 
the influence of other factors possibly associated with 
adherence.
Limitations of the study
One of the limitations of self-reporting adherence 
is the effect of social desirability, which can be 
more accentuated in the elderly population by the 
responsibility that society imposes on the elderly to 
care for themselves(20). For this reason, the occurrence 
of overestimation in the reporting of desired behavior 
is possible and has been shown in a similar study(21). 
However, the association of the measurements used in 
our study allowed the detection with greater sensibility 
of the problem of nonadherence among the elderly 
studied, ratifying the relevance of the theme in this 
population.
The second limitation concerns the Morisky’s 
scale reliability level, which tends to oscillate with wide 
variability in the different populations studied, mainly 
when employed in the form of dichotomous scales (yes/
no type), with registers of values (Cronbach’s alpha) 
between 0.18 and 0.61(22). In our study, Cronbach’s 
alpha coefficient was 0.41, indicating reliability lower 
than the desirable. Even so, it should be considered 
that the sample presented low levels of study and the 
internal consistency of the scale may be damaged by the 
fact of being composed of only four items. Despite the 
low reliability, the Morisky scale is still used worldwide 
given its accessibility and the lack of valid and reliable 
questionnaires that assess adherence and the factors 
related to it(23).
Conclusion
The adherence to the antidiabetic treatment was 
smaller among the patients with lower monthly income 
and the use of a larger number of medications has been 
related to individual risk factors for nonadherence. One 
of the determinant factors for the smaller proportion of 
adherence was the interruption of medication by the 
patient’s perception of adverse events. The elderly’s 
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perception of how much the drop in visual acuity 
interferes negatively in his HRQoL has demonstrated to 
compromise adherence. These findings provide for nurses 
evidence of the need for developing and evaluating new 
strategies to reduce the risk of nonadherence among the 
elderly with DR.
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